Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





FlashDx Launches New Respiratory and MRSA/SA Panels at MEDICA 2025

By LabMedica International staff writers
Posted on 17 Nov 2025

FlashDx is introducing two new molecular diagnostic assays at MEDICA 2025—the Respiratory Panel 2 and the MRSA/SA Panel. More...

The launch of these assays further extends FlashDx’s multiplex molecular testing portfolio, reinforcing the company’s commitment to advancing near-patient molecular diagnostics through innovation and automation. FlashDx will also demonstrate its fully automated multiplex molecular diagnostic system, powered by its proprietary sSPRT (semi-Solid Phase Real-Time PCR) technology.

The company is debuting Respiratory Panel 2, which targets additional respiratory pathogens to complement the existing Respiratory Panel 1.1. By broadening organism coverage, the new panel is intended to increase diagnostic flexibility while maintaining a syndromic testing approach. FlashDx is also launching an MRSA/SA Panel for rapid and precise detection of Methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), addressing routine screening and infection control needs in hospitals and clinics.

FlashDx is demonstrating its sSPRT powered platform at MEDICA 2025. The sSPRT platform enables rapid, accurate, and multiplex pathogen detection within a fully integrated “sample-to-result” workflow, designed to meet the growing needs of infectious disease and reproductive health diagnostics. Built to comply with the EU’s stringent IVD Regulation standards, the system maintains full regulatory integrity without sacrificing speed or flexibility. Its expandable, multi-slot instrumentation provides true random access to a wide range of disease panels and sample types—anytime and anywhere—allowing laboratories to scale testing confidently while meeting global quality and safety requirements

Attendees can meet FlashDx in Hall 3, Booth H26 at MEDICA 2025 to review the new assays and discuss opportunities for collaboration. Founded by U.S. and European industry experts with Silicon Valley know-how, FlashDx offers a turnkey, sample-to-answer platform and a portfolio of syndromic infectious disease cartridges, with plans to expand into oncology and other disease areas.

Related Links:
FlashDx

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Manual Pipetting Aid
Pipette Controllers macro
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.